World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
34396
World Ranking
12101
National Ranking
6209

Elizabeth A. Mittendorf publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Elizabeth A. Mittendorf sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 681 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Elizabeth A. Mittendorf D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Elizabeth A. Mittendorf sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Elizabeth A. Mittendorf is affiliated with Brigham and Women's Hospital in the United States. Their research primarily focuses on the fields of medicine and biochemistry, genetics, and molecular biology, with significant contributions to oncology and cancer research. Subfields in which they have an extensive publication record include pulmonary and respiratory medicine, pathology and forensic medicine, as well as radiology, nuclear medicine, and imaging.

Their scientific inquiry centers notably on topics related to breast cancer treatment studies, cancer immunotherapy and biomarkers, HER2/EGFR in cancer research, advanced breast cancer therapies, breast lesions and carcinomas, cancer genomics and diagnostics, and cancer treatment and pharmacology.

Frequent co-authors in their publications include:

  • Tari A. King
  • Sara M. Tolaney
  • Nabihah Tayob
  • Nancy U. Lin
  • Eric P. Winer

Their work has appeared repeatedly in several prominent journals, including:

  • Cancer Research
  • Annals of Surgical Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Breast Cancer Research and Treatment

Key recent publications by Elizabeth A. Mittendorf include:

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial, 2020, The Lancet
  • Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche, 2022, Cell
  • Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer, 2020, Nature Cancer
  • Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer, 2022, JAMA Oncology
  • Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer, 2020, Cancer Cell

Best Publications

  • Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

    Sonia A. Melo;Linda B. Luecke;Christoph Kahlert;Agustin F. Fernandez

  • Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

    Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt

  • PD-L1 Expression in Triple-Negative Breast Cancer

    Elizabeth A Mittendorf;Anne V Philips;Funda Meric-Bernstam;Na Qiao

  • Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

    Armando E. Giuliano;James L. Connolly;Stephen B. Edge;Elizabeth A. Mittendorf

  • Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

    Abigail S. Caudle;Wei T. Yang;Savitri Krishnamurthy;Elizabeth A. Mittendorf

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

    Jong-Ho Cha;Wen-Hao Yang;Weiya Xia;Yongkun Wei

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

    Judy C. Boughey;Karla V. Ballman;Huong T. Le-Petross;Linda M. McCall

  • Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

    Naoki Niikura;Jun Liu;Naoki Hayashi;Elizabeth Ann Mittendorf

  • Current Landscape of Immunotherapy in Breast Cancer: A Review

    Sylvia Adams;Margaret E. Gatti-Mays;Kevin Kalinsky;Larissa A. Korde

  • Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.

    Kelly K. Hunt;Min Yi;Elizabeth A. Mittendorf;Cynthia Guerrero

  • Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial

    Judy C. Boughey;Linda M. McCall;Karla V. Ballman;Elizabeth A. Mittendorf

  • Loss of HER2 Amplification Following Trastuzumab-based Neoadjuvant Systemic Therapy and Survival Outcomes

    Elizabeth A. Mittendorf;Yun Wu;Maurizio Scaltriti;Funda Meric-Bernstam

  • Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

    Elizabeth Ann Mittendorf;G. T. Clifton;J. P. Holmes;E. Schneble

  • Which threshold for ER positivity? a retrospective study based on 9639 patients

    M. Yi;Lei Huo;Kimberly Brooke Koenig;Elizabeth Ann Mittendorf

  • Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

    George E. Peoples;George E. Peoples;Jarrod P. Holmes;Jarrod P. Holmes;Matthew T. Hueman;Matthew T. Hueman;Elizabeth A. Mittendorf

  • Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy

    Jacqueline S. Jeruss;Elizabeth A. Mittendorf;Susan L. Tucker;Ana M. Gonzalez-Angulo

  • Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

    Elizabeth Ann Mittendorf;Guy T. Clifton;Jarrod P. Holmes;Kevin S. Clive

  • Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

    Judy C. Boughey;Karla V. Ballman;Kelly K. Hunt;Linda M. McCall

Frequent Co-Authors

Kelly K. Hunt
Kelly K. Hunt The University of Texas MD Anderson Cancer Center
Henry Mark Kuerer
Henry Mark Kuerer The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Alastair M. Thompson
Alastair M. Thompson Baylor College of Medicine
Gildy Babiera
Gildy Babiera The University of Texas MD Anderson Cancer Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Sara M. Tolaney
Sara M. Tolaney Harvard University
Eric P. Winer
Eric P. Winer Yale University
Jeffrey J. Molldrem
Jeffrey J. Molldrem The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine often involves exploring different educational paths and specializations. Many students start by looking for affordable options, such as the cheapest bsn programs online, which offer a convenient and cost-effective way to enter the nursing profession.

For registered nurses aiming to advance their education, there are also flexible cheapest bsn programs available fully online. These programs are designed for working professionals and can open doors to more specialized roles or leadership positions within healthcare.

If you’re considering a non-traditional route into advanced nursing, online msn programs for non nurses provide a fast track to earn a master’s degree even if you do not have a nursing background. These programs address the growing need for qualified healthcare providers in the USA.

Those interested in the highest levels of nursing education and leadership might explore phd nursing programs, which can lead to opportunities in research, academia, and policy-making. Online programs in this field offer flexible study options for aspiring nurse leaders.

Best Scientists Citing Elizabeth A. Mittendorf

Trending Scientists

Recently Published Articles